DOCSLIB.ORG

Fourth Joint LWPESJESPE Meeting 1993 Final Program

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fourth Joint LWPESJESPE Meeting 1993 Final Program 003 1-399819313305-0000$03.00/0 Vol. 33, No. 5, 1993 PEDIATRIC RESEARCH Printed in U.S.A. Copyright O 1993 International Pediatric Research Foundation, Inc. Fourth Joint LWPESJESPE Meeting 1993 Final Program FRIDAY, JUNE 4,1993 MORNING 9. Hormonal Monitoring and Side Effects of 8: 15 Opening ceremony Prenatal Dexamethasone Treatment for 21 - Fairmont Grand Ballroom Hydroxylase Deficiency Congenital Adrenal Melvin M. Grumbach, Chairman, Hyperplasia Organizing Committee SongyaPang Jo Anne Brasel, President, LWPES Department of Pediatrics Ieuan A. Hughes, President, ESPE University of Illinois College of Medicine, Chicago, IL PLENARY SESSION, I Fairmont Grand Ballroom 10. Prenatal Treatment of Congenital Adrenal 8:30 1. Lawson Wilkins Lecture: Hyperplasia Due to 21 -Hydroxylase Diabetes Mellitus, Type I - Islet Cell Deficiency: European Experience in 223 Destruction and Growth Studied in Pregnancies at Risk Transgenic Animal Models M. G. Forest Nora Sarvetnick I.N.S.E.R.M., Hopital Debrousse, Lyon, Department of Neuropharmacology France Scripps Research Institute, and LaJolla, CA H. G. Dorr Klinik fur Kinder and Jugendliche, 9:30 BREAK University Erlangen-Nurnberg, Erlangen, Germany CONCURRENT SYMPOSIA, I 11. Prenatal Treatment of Congenital Adrenal 10:OO-11:30 A.M. Hyperplasia SESSION A: Prenatal Diagnosis and P. Speiser Treatment of CAH Department of Pediatrics Fairmont Grand Ballroom The New York Hospital 10:OO 7. Molecular Pathology of 21 -Hydroxylase Cornell Medical Center, Deficiency New York, NY Tom Strachan Division of Human Genetics SESSION B: IDDM - Pharmacologic and University of Newcastle upon Tyne, UK Transplant Approaches to Therapy 10:20 8. Prenatal Diagnosis of Congenital Adrenal Mark Hopkins Peacock Court Hyperplasia Due to 21 -Hydroxylase 10:OO 12. Design and Use of Cellular Implants for Deficiency Treatment of Diabetes (IDDM) Yves Morel David Scharp I.N.S.E.R.M. Department of Surgery Hopital Debrousse, Washington University, Lyon, France St. Louis, MO 10:40 Prenatal Treatment Round Table Discussion Chair: Walter L. Miller Discussants: Drs. Dorr, Forest, Morel, Pang, Speiser, and Strachan 10:30 13. Antigen Directed Therapies to Prevent 297. Spontaneous Growth and Final Height in SGA Insulin Dependent Diabetes Infants Noel K. Maclaren J. Karlberg and K. Albertsson-Wikland Department of Pathology and 385. Insulin-Like Growth Factors (IGFs) Stimulate Laboratory Medicine VLA-4 Integrin Gene Expression in University of Florida, D~fferentiatingMouse Skeletal Muscle Cells Gainesville, FL S. M. Rosenthal and D. Hsiao 322. Increased Chromosome Fragility in Lymphocytes 11:00 14. Role of Glucose in Diabetic Complications of Short Normal Children Treated with Anthony Cerami Recombinant Human Growth Hormone The Picower Institute for Medical Research G. L. Spadoni, B. Tedeschi, M. L. Sanna, Manhasset, NY P. Vemole, D. Caporossi, S. Cianfarani, B. Nicoletti, B. Boscherini 11:30 LUNCHIPOSTERSIEXHIBITS 270. Radioimmunologic Determination of GHBP in Sera of Children with Shorl Stature AFTERNOON J. Kratzsch, W. F. Blum, T. Selisko, and E. Keller POSTER SYMPOSIUM 189. Advantages of the Computer-Aided Image 12:OO - 1:15 P.M. Analysis System for Estimating TW Skeletal Genibnormalities of the Growth Hormone Axis Maturity: Increased Reliability and a Continuous Stanford Court India Suite Scale 17 1. Exclusion of the GHRH Gene as a Candidate for J. M. Tanner, R. D. Gibbons, and R. D. Bock Most Cases of Familial Isolated Growth Hormone 359. Low Proconvertin (Factor VII) and Impaired Deficiency Blood Clotting Due to Growth Hormone L. A. Perez-Jurado, J. D. Cogan, J. A. Phillips, 111, Deficiency in the Rat and U. Francke L. S. G. Savendahl, K. G. Engstrom, and 137. Detection of Heterogeneous Growth Hormone K. Grankvist (GH)Gene Splicing by DNA Analysis of Dried Blood Spots From GH Deficient Subjects. SESSION B: NeuroendocrineIPituitary S. Miller-Davis, J. Cogan, J. A. Phillips, 111, Mark Hopkins Peacock Court R. D. G. Milner, A. Al-Ashwal, and N. A. Sakati 154. Characterization of the Molecular Defect in the 340. Spectrum of Growth Hormone Receptor Mutations Vasopressin-Neurophysin II Gene in a Family and Associated Haplotypes in Laron Syndrome with Autosomal Dominant Neurohypophyseal S. Amselem, F. Dastot, P. Duquesnoy, Diabetes Insipidus M-L. Sobrier, S. Vallex, B. Duriez, and D. R. Repaske and J. E. Browning M. Goossens 184. N-Methyl-D-Aspartate (NMDA)Stimulates LHRH 339. Molecular Analysis of Two Families with Laron Release via the NMDA Receptor in an LHRH Syndrome and Positive Growth Hormone Binding Neuronal Cell Line (GTl-I) Protein P. ~ahachoklertwattana,J. Sanchez, P. Duquesnoy, M-L. Sobrier, C. R. Buchanan, M. M. Grumbach, S. L. Kaplan, and B. Duriez, H. G. Maheshwari, M. 0. Savage, S. M. Rosenthal M-C. Postel-Vinnay, M. Norman, A. M. Cotterill, 153. Inhibition of GnRH Secretion by IGF-1 M. A. Preece, M. Goossens, and S. Amselem Degradation into a Sub-product Antagonist at 191. A New Type of Inherited Growth Hormone NMDA Receptors: An Effect Developing After the Deficiency: A Compound Heterozygote of a 6.7 Onset of Puberty KB Deletion, Including the GH-l Gene, and Two J. P. Bourguignon, A. Gerard, Base Deletion in the Third Exon of the GH-I Gene M. L. Alvarez Gonzalez, and P. Franchimont Y.Igarashi, T. Kamijo, M. Ogawa, Y. Nishi, 148. PIT-I Gene Expression in the Anterior Pituitary is N. Iwatani, H. Kono, T. Masumura, and J. Koga Modulated by Changes in Circulating Levels of Testosterone 221. Molecular Analysis of a Large Bedouin Kindred J. Argente, S. Gonzalez-Parra, J. A. Chowen, and with IGHD Type IB L.M. Garcia-Segura E. Leiberman, R. Carmi, Y. Limoni, H. Abdul 144. Sexual Dimorphism of Galanin Gene Expression Latif, M.R. Brown, and J.S. Parks in Growth Hormone-Releasing Hormone Neurons of the Rat During Development CONCURRENT ORAL PRESENTATIONS H. A. Delemarre-van de Waal, K. A. Burton, 1:30 - 3:00 p.m. E. B. Kabigting, D. K. Clifton, and R. A. Steiner SESSION A: Growth, Growth Factors, Growth Hormone, I Fairmont Grand Ballroom 11 2:45 150. Neonatal Testosterone Modulates the Number and 17. Therapeutic Response to Recombinant IGF-I Responsivity of Growth Hormone-Releasing in Thirty-Two Patients with Growth Hormone (GHRH)Neurons Hormone Insensitivity J. A. Chowen, S. Gonzalez-Parra, M. 0. Savage L. M. Garcia-Segura, and J. Argente St. Bartholomew's Hospital, London, UK SESSION C: Fetal, Neonatal, Pregnancy Stanford Court Ballroom 18. One Year Treatment with IGF-I of Children 1:30 405. Pregnancy Luctogens in the Rat Conceptus: with Laron Syndrome Circulating Levels, Distribution of Binding, and Zvi Laron Expression of Receptor mRNA Children's Medical Center of Israel M. S. Freemark, K. Kirk, K. Pihoker, P. Driscoll, Petah Tikva, Israel and M. Robertson Effects of Prolonged IGF-I Treatment in 1 :45 408. Anti-Mullerian Hormone in Early Human Development Children with Growth Hormone Insensitivity N. Josso, I. Lamarre, and J.Y. Picard Syndrome (GHIS) Louis Underwood 2:00 413. Protein Kinase C Isotype Expression During Division of Pediatric Endocrinology Early Pituitary Development L. Cuttler, M. Axline, and A.P. Fields University of North Carolina, Chapel Hill, NC SESSION C(cont'd): Calcium/Phosphorus, Bone 2: 15 470. Nephrocalcinosis (NC)Due to 4:30 Discussion Hyperparathyroidism in X-Linked Hypophosphatemic Rickets (XLHR)-Results of a SESSION B: Neuroendocrinology of Retrospective Study in 155 Children and Reproduction Adolescents Stanford Court Ballroom K. Mohnike, K. Knye, M. Cagnoli, K. Kruse, 19. Regulation of GnRH Release from GnRH E. Schoenau, and the German Phosphate-Diabetes Neuronal Cell Lines Study Group Richard I. Weiner 2:30 473. VGR-l/BMP-6 Induces Osteogenic Differentiation Reproductive Endocrinology Center in Mesenchymal Cells University of California, S. E. Gitelman, M. Kirk, A. J. Kahn, and San Francisco, CA R. Derynck 20. Kallmann Syndrome: A Defect in Neuronal 2:45 467. Ultrasound Velocity in the 0s Calcis, Thumb, and Patella During Childhood as Indicator of Bone Target Recognition Density Andrea Ballabio E. Schoenau, A. Rademacher, K. Klein, and Institute for Molecular Genetics Baylor D. Michalk College of Medicine, Houston, TX CONCURRENT SYMPOSIA, II Spatio-Temporal Patterns of Hormone and 3:OO-4:30 P.M. Hormone Transcription Factor Gene SESSION A: Insulin-Like Growth Factors Expression During the Development and Fairmont Grand Ballroom Mature Function of the Neuroendocrine 3:00 15. In Vivo Metabolic Actions of IGF-l System Jurgen Zapf Lany W.Swanson Department of Medicine Department of Biological Sciences University Hospital, University of Southern California, Zurich, Switzerland Los Angeles, CA Round Table Discussion: IGF-1 Treatment of SESSION C: Abnormalities of Steroidogenesis Growth Hormone Insensitivity and Metabolism Mark Hopkins Peacock Court 3:30 16. Changes in Body and Bone Composition in 3:OO 22. Molecular Basis of Congenital Adrenal Adolescent Growth Hormone Receptor Hypelplasia Due to 3beta-Hydroxysteroid Deficient (GHRD)Patients Receiving rhIGF- Dehydrogenase Deficiency I and a GnRH Analog Jacques Simard Jaime Guevara-Aguirre MRC Group in Molecular Endocrinology IEMIR CHUL Research Center, Quito, Ecuador . Quebec, Canada 111 3:30 23. Ilbeta-Hydroxylase and Hypertension 4:30 BREAK P. C. White Cornell University PLENARY SESSION, II Medical College, Fairmont Grand Ballroom New York, NY 5:00 2. PIT-1 and Its Naturally Occurring Genetic Mutations: Answers and Questions about the Steroid Salpha-Reductase Type 2 Deficiency 4:00 24. Molecular Biology of Pituitary Development David W. Russell and
Load more

Recommended publications
  • Transferrin Variants and Conjugates
    (19) TZZ Z ¥ T (11) EP 2 604 623 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 19.06.2013 Bulletin 2013/25 C07K 14/79 (2006.01) A61K 47/48 (2006.01) A61K 38/40 (2006.01) C12N 5/10 (2006.01) (21) Application number: 12189421.6 (22) Date of filing: 08.08.2008 (84) Designated Contracting States: • Friis, Esben Peter AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 2730 Herlev (DK) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT • Hay, Joanna RO SE SI SK TR Nottingham, Nottinghamshire NG2 6QW (GB) • Finnis, Christopher John Arthur (30) Priority: 08.08.2007 EP 07114012 Nottingham, Nottinghamshire NG7 1JB (GB) 02.04.2008 EP 08153938 (74) Representative: Williams, Rachel Clare (62) Document number(s) of the earlier application(s) in Novozymes Biopharma UK Limited accordance with Art. 76 EPC: Castle Court 08787067.1 / 2 201 036 59 Castle Boulevard Nottingham (71) Applicant: Novozymes Biopharma DK A/S Nottinghamshire NG7 1FD (GB) 2880 Bagsvaerd (DK) Remarks: (72) Inventors: This application was filed on 22-10-2012 as a • Sleep, Darrell divisional application to the application mentioned Nottingham, Nottinghamshire NG2 5DS (GB) under INID code 62. (54) Transferrin variants and conjugates (57) Based on the three-dimensional structure of "thiotransferrin"). The variant polypeptide may be conju- transferrin, the inventors have designed variant polypep- gated through the sulphur atom of the Cysteine residue tides (muteins) which have one or more Cysteine resi- to a bioactive compound. dues with a free thiol group (hereinafter referred to as EP 2 604 623 A2 Printed by Jouve, 75001 PARIS (FR) EP 2 604 623 A2 Description Reference to sequence listing 5 [0001] This application contains a Sequence Listing in computer readable form.
    [Show full text]
  • Repercussions of Inborn Errors of Immunity on Growth☆ Jornal De Pediatria, Vol
    Jornal de Pediatria ISSN: 0021-7557 ISSN: 1678-4782 Sociedade Brasileira de Pediatria Goudouris, Ekaterini Simões; Segundo, Gesmar Rodrigues Silva; Poli, Cecilia Repercussions of inborn errors of immunity on growth☆ Jornal de Pediatria, vol. 95, no. 1, Suppl., 2019, pp. S49-S58 Sociedade Brasileira de Pediatria DOI: https://doi.org/10.1016/j.jped.2018.11.006 Available in: https://www.redalyc.org/articulo.oa?id=399759353007 How to cite Complete issue Scientific Information System Redalyc More information about this article Network of Scientific Journals from Latin America and the Caribbean, Spain and Journal's webpage in redalyc.org Portugal Project academic non-profit, developed under the open access initiative J Pediatr (Rio J). 2019;95(S1):S49---S58 www.jped.com.br REVIEW ARTICLE ଝ Repercussions of inborn errors of immunity on growth a,b,∗ c,d e Ekaterini Simões Goudouris , Gesmar Rodrigues Silva Segundo , Cecilia Poli a Universidade Federal do Rio de Janeiro (UFRJ), Faculdade de Medicina, Departamento de Pediatria, Rio de Janeiro, RJ, Brazil b Universidade Federal do Rio de Janeiro (UFRJ), Instituto de Puericultura e Pediatria Martagão Gesteira (IPPMG), Curso de Especializac¸ão em Alergia e Imunologia Clínica, Rio de Janeiro, RJ, Brazil c Universidade Federal de Uberlândia (UFU), Faculdade de Medicina, Departamento de Pediatria, Uberlândia, MG, Brazil d Universidade Federal de Uberlândia (UFU), Hospital das Clínicas, Programa de Residência Médica em Alergia e Imunologia Pediátrica, Uberlândia, MG, Brazil e Universidad del Desarrollo,
    [Show full text]
  • Human Neurophysin II Antibody
    Human Neurophysin II Antibody Monoclonal Mouse IgG2B Clone # 62865 Catalog Number: MAB009 DESCRIPTION Species Reactivity Human Specificity Detects human Neurophysin II in direct ELISAs. Source Monoclonal Mouse IgG2B Clone # 62865 Purification Protein A or G purified from ascites Immunogen Synthetic peptide containing human Neurophysin II Accession # P01186 Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 μm filtered solution in PBS. APPLICATIONS Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website. Recommended Sample Concentration Immunohistochemistry 5-25 µg/mL See Below DATA Immunohistochemistry Neurophysin II in Human Brain Hippocampus Tissue. Neurophysin II was detected in immersion fixed paraffin- embedded sections of human brain hippocampus tissue using Mouse Anti- Human Neurophysin II Monoclonal Antibody (Catalog # MAB009) at 5 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent- Basic (Catalog # CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to neurons. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents. PREPARATION AND STORAGE Reconstitution Reconstitute at 0.5 mg/mL in sterile PBS. Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs.
    [Show full text]
  • Diversity of Central Oxytocinergic Projections
    Cell and Tissue Research (2019) 375:41–48 https://doi.org/10.1007/s00441-018-2960-5 REVIEW Diversity of central oxytocinergic projections Gustav F. Jirikowski1 Received: 21 September 2018 /Accepted: 6 November 2018 /Published online: 29 November 2018 # Springer-Verlag GmbH Germany, part of Springer Nature 2018 Abstract Localization and distribution of hypothalamic neurons expressing the nonapeptide oxytocin has been extensively studied. Their projections to the neurohypophyseal system release oxytocin into the systemic circulation thus controlling endocrine events associated with reproduction in males and females. Oxytocinergic neurons seem to be confined to the ventral hypothalamus in all mammals. Groups of such cells located outside the supraoptic and the paraventricular nuclei are summarized as Baccessory neurons.^ Although evolutionary probably associated with the classical magocellular nuclei, accessory oxytocin neurons seem to consist of rather heterogenous groups: Periventricular oxytocin neurons may gain contact to the third ventricle to secrete the peptide into the cerebrospinal fluid. Perivascular neurons may be involved in control of cerebral blood flow. They may also gain access to the portal circulation of the anterior pituitary lobe. Central projections of oxytocinergic neurons extend to portions of the limbic system, to the mesencephalon and to the brain stem. Such projections have been associated with control of behaviors, central stress response as well as motor and vegetative functions. Activity of the different oxytocinergic systems seems to be malleable to functional status, strongly influenced by systemic levels of steroid hormones. Keywords Hypothalamo neurohypophyseal system . Circumventricular organs . Liquor contacting neurons . Perivascular system . Limbic system Introduction been shown to occur in prostate, gonads, or skin, OTexpression in the brain seems to be confined to the hypothalamus.
    [Show full text]
  • Pnas11138correction 14002..14003
    Corrections MEDICAL SCIENCES Correction for “Regulation of bone remodeling by vasopressin New, Alberta Zallone, and Mone Zaidi, which appeared in issue 46, explains the bone loss in hyponatremia,” by Roberto Tamma, November 12, 2013, of Proc Natl Acad Sci USA (110:18644–18649; Li Sun, Concetta Cuscito, Ping Lu, Michelangelo Corcelli, first published October 28, 2013; 10.1073/pnas.1318257110). Jianhua Li, Graziana Colaianni, Surinder S. Moonga, Adriana The authors note that Fig. 1 appeared incorrectly. The cor- Di Benedetto, Maria Grano, Silvia Colucci, Tony Yuen, Maria I. rected figure and its legend appear below. Fig. 1. Bone cells express Avprs. Immunofluorescence micrographs (A) and Western immunoblotting (B) show the expression of Avpr1α in osteoblasts and osteoclasts, and as a function of osteoblast (mineralization) and osteoclast (with Rankl) differentiation. The expression of Avp (ligand) and Avpr1α (receptor) in osteoblasts is regulated by 17β-estradiol, as determined by quantitative PCR (C) and Western immunoblotting (D). (Magnification: A,63×.) Because Avp is a small peptide, its precursor neurophysin II is measured. Statistics: Student t test, P values shown compared with 0 h. Stimulation of Erk phosphorylation − (p-Erk) as a function of total Erk (t-Erk) by Avp (10 8 M) in osteoclast precursors (preosteoclasts), osteoclasts (OC), and osteoblasts establishes functionality of − the Avpr1α in the presence or absence of the receptor inhibitor SR49059 (10 8 M) (E). Western immunoblotting showing the expression of Avpr2 in pre- −/− osteoclasts, OCs (F), and osteoblasts (G) isolated from Avpr1α mice, as well as in MC3T3.E1 osteoblast precursors (G). Functionality of Avpr2 was confirmed −/− by the demonstration that cells from Avpr1α mice remained responsive to AVP in reducing the expression of osteoblast differentiation genes, namely Runx2, Osx, Bsp, Atf4, Opn, and Osteocalcin (quantitative PCR, P values shown) (H).
    [Show full text]
  • Prevalence and Incidence of Rare Diseases: Bibliographic Data
    Number 1 | January 2019 Prevalence and incidence of rare diseases: Bibliographic data Prevalence, incidence or number of published cases listed by diseases (in alphabetical order) www.orpha.net www.orphadata.org If a range of national data is available, the average is Methodology calculated to estimate the worldwide or European prevalence or incidence. When a range of data sources is available, the most Orphanet carries out a systematic survey of literature in recent data source that meets a certain number of quality order to estimate the prevalence and incidence of rare criteria is favoured (registries, meta-analyses, diseases. This study aims to collect new data regarding population-based studies, large cohorts studies). point prevalence, birth prevalence and incidence, and to update already published data according to new For congenital diseases, the prevalence is estimated, so scientific studies or other available data. that: Prevalence = birth prevalence x (patient life This data is presented in the following reports published expectancy/general population life expectancy). biannually: When only incidence data is documented, the prevalence is estimated when possible, so that : • Prevalence, incidence or number of published cases listed by diseases (in alphabetical order); Prevalence = incidence x disease mean duration. • Diseases listed by decreasing prevalence, incidence When neither prevalence nor incidence data is available, or number of published cases; which is the case for very rare diseases, the number of cases or families documented in the medical literature is Data collection provided. A number of different sources are used : Limitations of the study • Registries (RARECARE, EUROCAT, etc) ; The prevalence and incidence data presented in this report are only estimations and cannot be considered to • National/international health institutes and agencies be absolutely correct.
    [Show full text]
  • MECHANISMS in ENDOCRINOLOGY: Novel Genetic Causes of Short Stature
    J M Wit and others Genetics of short stature 174:4 R145–R173 Review MECHANISMS IN ENDOCRINOLOGY Novel genetic causes of short stature 1 1 2 2 Jan M Wit , Wilma Oostdijk , Monique Losekoot , Hermine A van Duyvenvoorde , Correspondence Claudia A L Ruivenkamp2 and Sarina G Kant2 should be addressed to J M Wit Departments of 1Paediatrics and 2Clinical Genetics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, Email The Netherlands [email protected] Abstract The fast technological development, particularly single nucleotide polymorphism array, array-comparative genomic hybridization, and whole exome sequencing, has led to the discovery of many novel genetic causes of growth failure. In this review we discuss a selection of these, according to a diagnostic classification centred on the epiphyseal growth plate. We successively discuss disorders in hormone signalling, paracrine factors, matrix molecules, intracellular pathways, and fundamental cellular processes, followed by chromosomal aberrations including copy number variants (CNVs) and imprinting disorders associated with short stature. Many novel causes of GH deficiency (GHD) as part of combined pituitary hormone deficiency have been uncovered. The most frequent genetic causes of isolated GHD are GH1 and GHRHR defects, but several novel causes have recently been found, such as GHSR, RNPC3, and IFT172 mutations. Besides well-defined causes of GH insensitivity (GHR, STAT5B, IGFALS, IGF1 defects), disorders of NFkB signalling, STAT3 and IGF2 have recently been discovered. Heterozygous IGF1R defects are a relatively frequent cause of prenatal and postnatal growth retardation. TRHA mutations cause a syndromic form of short stature with elevated T3/T4 ratio. Disorders of signalling of various paracrine factors (FGFs, BMPs, WNTs, PTHrP/IHH, and CNP/NPR2) or genetic defects affecting cartilage extracellular matrix usually cause disproportionate short stature.
    [Show full text]
  • Update on New GH-IGF Axis Genetic Defects
    review Update on new GH-IGF axis genetic defects Gabriela A. Vasques1,2 1 Unidade de Endocrinologia https://orcid.org/0000-0002-6455-8682 Genética, Laboratório de Endocrinologia Celular e Nathalia L. M. Andrade1,2 https://orcid.org/0000-0002-1628-7881 Molecular (LIM25), Hospital das Clínicas, Faculdade de Fernanda A. Correa2 Medicina, Universidade de São https://orcid.org/0000-0003-2107-9494 Paulo, São Paulo, SP, Brasil 2 Alexander A. L. Jorge1,2 Unidade de Endocrinologia do https://orcid.org/0000-0003-2567-7360 Desenvolvimento, Laboratório de Hormônios e Genética Molecular (LIM42), Hospital das Clínicas, Faculdade de ABSTRACT Medicina, Universidade de São The somatotropic axis is the main hormonal regulator of growth. Growth hormone (GH), also known Paulo, São Paulo, SP, Brasil as somatotropin, and insulin-like growth factor 1 (IGF-1) are the key components of the somatotropic axis. This axis has been studied for a long time and the knowledge of how some molecules could Correspondence to: promote or impair hormones production and action has been growing over the last decade. The Alexander A. L. Jorge Laboratório de Endocrinologia enhancement of large-scale sequencing techniques has expanded the spectrum of known genes and Celular e Molecular (LIM25), several other candidate genes that could affect the GH-IGF1-bone pathway. To date, defects in more Faculdade de Medicina, than forty genes were associated with an impairment of the somatotropic axis. These defects can Universidade de São Paulo Av. Dr. Arnaldo, 455, affect from the secretion of GH to the bioavailability and action of IGF-1. Affected patients present a 5º andar, sala 5.340 large heterogeneous group of conditions associated with growth retardation.
    [Show full text]
  • Genetic Disorder
    Genetic disorder Single gene disorder Prevalence of some single gene disorders[citation needed] A single gene disorder is the result of a single mutated gene. Disorder Prevalence (approximate) There are estimated to be over 4000 human diseases caused Autosomal dominant by single gene defects. Single gene disorders can be passed Familial hypercholesterolemia 1 in 500 on to subsequent generations in several ways. Genomic Polycystic kidney disease 1 in 1250 imprinting and uniparental disomy, however, may affect Hereditary spherocytosis 1 in 5,000 inheritance patterns. The divisions between recessive [2] Marfan syndrome 1 in 4,000 and dominant types are not "hard and fast" although the [3] Huntington disease 1 in 15,000 divisions between autosomal and X-linked types are (since Autosomal recessive the latter types are distinguished purely based on 1 in 625 the chromosomal location of Sickle cell anemia the gene). For example, (African Americans) achondroplasia is typically 1 in 2,000 considered a dominant Cystic fibrosis disorder, but children with two (Caucasians) genes for achondroplasia have a severe skeletal disorder that 1 in 3,000 Tay-Sachs disease achondroplasics could be (American Jews) viewed as carriers of. Sickle- cell anemia is also considered a Phenylketonuria 1 in 12,000 recessive condition, but heterozygous carriers have Mucopolysaccharidoses 1 in 25,000 increased immunity to malaria in early childhood, which could Glycogen storage diseases 1 in 50,000 be described as a related [citation needed] dominant condition. Galactosemia
    [Show full text]
  • Laron Syndrome
    Laron syndrome Description Laron syndrome is a rare form of short stature that results from the body's inability to use growth hormone, a substance produced by the brain's pituitary gland that helps promote growth. Affected individuals are close to normal size at birth, but they experience slow growth from early childhood that results in very short stature. If the condition is not treated, adult males typically reach a maximum height of about 4.5 feet; adult females may be just over 4 feet tall. Other features of untreated Laron syndrome include reduced muscle strength and endurance, low blood sugar levels (hypoglycemia) in infancy, small genitals and delayed puberty, hair that is thin and fragile, and dental abnormalities. Many affected individuals have a distinctive facial appearance, including a protruding forehead, a sunken bridge of the nose (saddle nose), and a blue tint to the whites of the eyes (blue sclerae). Affected individuals have short limbs compared to the size of their torso, as well as small hands and feet. Adults with this condition tend to develop obesity. However, the signs and symptoms of Laron syndrome vary, even among affected members of the same family. Studies suggest that people with Laron syndrome have a significantly reduced risk of cancer and type 2 diabetes. Affected individuals appear to develop these common diseases much less frequently than their unaffected relatives, despite having obesity (a risk factor for both cancer and type 2 diabetes). However, people with Laron syndrome do not seem to have an increased lifespan compared with their unaffected relatives. Frequency Laron syndrome is a rare disorder.
    [Show full text]
  • Recent Applications of Retro-Inverso Peptides
    International Journal of Molecular Sciences Review Recent Applications of Retro-Inverso Peptides Nunzianna Doti 1, Mario Mardirossian 2, Annamaria Sandomenico 1 , Menotti Ruvo 1,* and Andrea Caporale 3,* 1 Institute of Biostructures and Bioimaging (IBB), National Research Council (CNR), 80134 Napoli, Italy; [email protected] (N.D.); [email protected] (A.S.) 2 Department of Medicine, Surgery and Health Sciences, University of Trieste, 34149 Trieste, Italy; [email protected] 3 Institute of Crystallography (IC), National Research Council (CNR), 34149 Trieste, Italy * Correspondence: [email protected] (M.R.); [email protected] (A.C.) Abstract: Natural and de novo designed peptides are gaining an ever-growing interest as drugs against several diseases. Their use is however limited by the intrinsic low bioavailability and poor stability. To overcome these issues retro-inverso analogues have been investigated for decades as more stable surrogates of peptides composed of natural amino acids. Retro-inverso peptides possess reversed sequences and chirality compared to the parent molecules maintaining at the same time an identical array of side chains and in some cases similar structure. The inverted chirality renders them less prone to degradation by endogenous proteases conferring enhanced half-lives and an increased potential as new drugs. However, given their general incapability to adopt the 3D structure of the parent peptides their application should be careful evaluated and investigated case by case. Here, we review the application of retro-inverso peptides in anticancer therapies, in immunology, in neurodegenerative diseases, and as antimicrobials, analyzing pros and cons of this interesting subclass of molecules. Keywords: retro-inverso peptides; anticancer peptides; drug delivery; peptide antigens; Aβ; IAPP; Citation: Doti, N.; Mardirossian, M.; antimicrobial peptides Sandomenico, A.; Ruvo, M.; Caporale, A.
    [Show full text]
  • Blueprint Genetics Comprehensive Growth Disorders / Skeletal
    Comprehensive Growth Disorders / Skeletal Dysplasias and Disorders Panel Test code: MA4301 Is a 374 gene panel that includes assessment of non-coding variants. This panel covers the majority of the genes listed in the Nosology 2015 (PMID: 26394607) and all genes in our Malformation category that cause growth retardation, short stature or skeletal dysplasia and is therefore a powerful diagnostic tool. It is ideal for patients suspected to have a syndromic or an isolated growth disorder or a skeletal dysplasia. About Comprehensive Growth Disorders / Skeletal Dysplasias and Disorders This panel covers a broad spectrum of diseases associated with growth retardation, short stature or skeletal dysplasia. Many of these conditions have overlapping features which can make clinical diagnosis a challenge. Genetic diagnostics is therefore the most efficient way to subtype the diseases and enable individualized treatment and management decisions. Moreover, detection of causative mutations establishes the mode of inheritance in the family which is essential for informed genetic counseling. For additional information regarding the conditions tested on this panel, please refer to the National Organization for Rare Disorders and / or GeneReviews. Availability 4 weeks Gene Set Description Genes in the Comprehensive Growth Disorders / Skeletal Dysplasias and Disorders Panel and their clinical significance Gene Associated phenotypes Inheritance ClinVar HGMD ACAN# Spondyloepimetaphyseal dysplasia, aggrecan type, AD/AR 20 56 Spondyloepiphyseal dysplasia, Kimberley
    [Show full text]